Abstract
Interleukin (IL)-17 and IL-23 inhibitors are both approved for the treatment of moderate-to-severe plaque psoriasis (PsO), as well as psoriatic arthritis (PsA). In the absence of head-to-head studies, it is not clear which agent is better suited to treat patients with moderate-to-severe PsO and mild PsA. During the 2022 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) conference, Dr. April Armstrong and Dr. Joseph Merola debated which of these 2 biologic classes should be used in this patient population. Armstrong argued in favor of IL-17 inhibition, whereas Merola presented reasons for IL-23 inhibition. An overview of their main arguments is described in this manuscript.
Publisher
The Journal of Rheumatology
Subject
Immunology,Immunology and Allergy,Rheumatology
Reference25 articles.
1. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
2. Mease P , Landewé R , Rahman P , Effect of SEC on radiographic progression through 2 years in patients with active psoriatic arthritis: end-of-study results from a phase III study [abstract]. Arthritis Rheumatol 2019;71 Suppl 10.
3. Data on file . CAIN457F2342 Clinical study report interim analysis – week 24. Novartis Pharmaceuticals Corporation; 2018.
4. Cosentyx . Prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corp.; 2021.
5. Data on file . CAIN457F2342 (FUTURE 5): 2-Year Data Analysis Report. Novartis Pharmaceuticals Corp.; May 2019.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献